Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series

ME Rahman Shuvo*[,1] MBBS, Max Schwiening*[,2] BA, Felipe Soares[4,5] PhD, Oliver Feng[3] PhD, Susana Abreu[2] PhD, Niki Veale[1] MBBS, William Thomas[1] MBBS, AA Roger Thompson[4] PhD, Richard J Samworth[3] PhD, Nicholas W Morrell[1,2] PhD, Stefan J Marciniak[1,2] PhD, Elaine Soon[1,2] PhD (0000-0002-5744-5014)

[1]Department of Respiratory Medicine, Level 5, Box 157, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK - MER Shuvo (Specialist trainee), N Veale (Specialist trainee), W Thomas (Consultant), NW Morrell (Professor), SJ Marciniak (Professor), E Soon (Clinician Scientist).

[2]Cambridge Institute for Medical Research, University of Cambridge, Keith Peters Building, Hills Rd, Cambridge CB2 0XY, UK – M Schwiening (PhD candidate), S Abreu (Postdoctoral researcher), SJ Marciniak (Professor), E Soon (Clinician Scientist).

[3]Statistical Laboratory, Centre for Mathematical Sciences, Wilberforce Road, Cambridge, CB3 0WB – O Feng (Postdoctoral researcher), RJ Samworth (Professor).

[4]Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Beech Hill Road, Sheffield S10 2RX – F Soares (PhD candidate), AAR Thompson (Clinician Scientist).

[5] Universidade Federal do Rio Grande do Sul, Av. Paulo Gama, 110 Secretaria de Comunicação Social - 8º andar - Reitoria - Farroupilha, Porto Alegre - RS, 90040-060, Brazil - F Soares (PhD candidate).

*Contributed equally.

Collaborators

Wang J[1], Rzymski P[2], Patel A[3] and Altintop TU[4]

[1]Northern Health, Northern Hospital, 185 Cooper St Epping, Melbourne, VIC, 3076, Australia.

[2]Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Poznań, Poland.

[3]Infectious Diseases Clinic, Institute of Medical Sciences, Navarangpura, Ahmedabad, 380009, India.

[4]Department of Medical Microbiology, Amasya University Sabuncuoglu Serefeddin Research and Training Hospital, Amasya, Turkey.

Correspondence to:

Elaine Soon

Cambridge Institute for Medical Research,

Keith Peters Building, Cambridge Biomedical Campus, Hills Rd, Cambridge CB2 0XY, UK.

Fax number: ++44 (1223) 336846

Telephone number: ++44 (1223) 336788

E-mail: eels2@cam.ac.uk , e_soon@hotmail.co.uk

Contributorship

MERS, FS, WT, and NV collected data, reviewed source manuscripts, and helped analyze data. MS, FS and SA contributed to the creation of online resources. OF and RJS performed statistical analyses. RT, NWM and SJM contributed to the planning, organization, and funding of the study. ES conceptualized and organized the study, performed data analyses, funded the study, and takes responsibility for the integrity of the work as a whole. All authors contributed to the writing and critical revision of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Acknowledgements

We thank Ms Natalie Doughty, Mr Chris Davies, Dr Benjamin Dunmore, and Mr Nikita Zubkov who provided general public and patient input into accessibility of data, website, and software.

Many thanks also to all root study authors, patients and essential workers who have selflessly shared their time and data.

Copyright for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display and store the Contribution, (ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, (iii) create any other derivative work(s) based on the Contribution, (iv) to exploit all subsidiary rights in the Contribution, (v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, (vi) licence any third party to do any or all of the above.

Disclosures

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest / and declare: no support from any commercial organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval

Ethical approval was obtained from the National Health System (UK) Health Research Authority via the Integrated Research Application System (reference 281880) for analysis of the Cambridge (UK) data. All the other data has been published and is in the public domain.

Funding

ES and MS are supported by the UK Medical Research Council (MR/R008051/1); the British Medical Association (the Josephine Lansdell Award); and the Association of Physicians of Great Britain and Ireland (Young Investigator Award to ES); the Wellcome Trust ISSF and the Cambridge BHF Centre of Research Excellence (RE/18/1/34212). MES and WT are full-time NHS physicians who have volunteered their time for this work. FS received in-kind funding by the AWS Diagnostic Development Initiative and Google TPU Research Cloud. NV is supported by a BLF-Papworth Fellowship from the British Lung Foundation and the Victor Dahdaleh Foundation (VPDCF17-18). AART is supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/33281). OF is funded by the StatScale programme (EP/N031938/1). RJS is supported by Engineering and Physical Sciences Research Council grants EP/P031447/1 and EP/N031938/1, as well as ERC Advanced Grant 101019498. SA and SJM are funded by the British Lung Foundation (VPDCF17-18), the Medical Research Council, UK (MR/V028669/1), the NIHR Cambridge Biomedical Campus (BRC-1215-20014) and the Royal Papworth NHS Trust. NWM is supported by the British Heart Foundation (SP/12/12/29836), the Cambridge BHF Centre of Research Excellence (RE/18/1/34212), the UK Medical Research Council (MR/K020919/1), the Dinosaur Trust, BHF Programme grants to NWM (RG/13/4/30107), and the NIHR Cambridge Biomedical Research Centre.

The funders did not have a role in the study design, data collection or analyses or the decision to submit for publication.

Data sharing: The relevant anonymized data will be shared on reasonable request.

Total word count: 3,536

Abstract word count: 249

Summary box

What is already known on this topic

Biomarkers such as CRP, D-dimer, and interleukin-6 have been proven to have prognostic value in SARS-CoV-2. However prognostic scores using these as building blocks have performed unevenly in different locations.

What this study adds

Commonly used biomarkers for SARS-CoV-2 have different efficacies in different parts of the world. For example, admission CRP and interleukin-6 levels are good prognostic markers for mortality in Asian countries but only average in Europe and North America. Prognostic markers and scores cannot be 'transplanted' from one region to another. This has implications not just for SARS-CoV-2 but also for scores in other conditions. We note a significant lag from the pandemic advent to data availability and this has no doubt impacted on patient care.

How this study might affect research, practice, or policy

Biomarkers and by extension prognostic scores should be validated in their target country/population before use. The infrastructure for data collection and analysis should be put in place so that this process can happen rapidly (ideally in an automated manner), in case of another pandemic.

ABSTRACT

Rationale: Sophisticated prognostic scores have been proposed for SARS-CoV-2 but do not always perform consistently. We conducted these meta-analyses to uncover why and to investigate the impact of vaccination and variants.

Methods: We searched the PubMed database for the keywords 'SARS-CoV-2' with 'biomarker' and 'mortality'. All studies published from 01/12/2020 to 31/03/2023 were surveyed. To aggregate the data, the *meta* library in R was used, and a random effects model fitted to obtain pooled AUCs and 95% confidence intervals for the European/North American, Asian, and overall datasets.

Results: Biomarker effectiveness varies significantly in different continents. Admission CRP levels are a good prognostic marker for mortality in Asian countries, with a pooled area under curve (AUC) of 0.83 (95%CI 0.80-0.85), but only an average predictor of mortality in Europe/North America, with a pooled AUC of 0.67 (95%CI 0.63-0.71, $P<0.0001$). We observed the same pattern for D-dimer and IL-6. This variability explains why the proposed prognostic scores did not perform evenly. Notably, urea and troponin had pooled AUCs ≥0.78 regardless of location, implying that end-organ damage at presentation is a key prognostic factor. Very little data is available for vaccinated and variant cohorts but it appears that inflammatory biomarkers are performing less well. We note a significant lag from the pandemic advent to data availability and this has no doubt impacted on patient care.

Conclusions: Biomarker efficacies vary considerably by region. It is imperative that the infrastructure for collecting clinical data should be put in place ahead of a future pandemic.

Introduction

SARS-CoV-2 is a novel beta coronavirus of zoonotic origin first identified in Wuhan, China at the end of 2019, which led to the introduction of a Public Health Emergency of International Concern between February 2020 and May 2023. SARS-CoV-2 differs from previous viral threats in showing marked transmissibility during the asymptomatic/very early symptomatic stage[1] and person-to-person transmission by both airborne and fomite routes[2]. At the beginning of the pandemic, there was no previous immunity, no known effective antiviral treatment, and no vaccine, resulting in a global death toll of over six million (https://covid19.who.int/).

Due to the overwhelming number of cases and the significant morbidity and mortality associated with SARS-CoV-2, reliable prognostic scores are critically important to maximize survivorship and optimize the use of limited resources. Sophisticated scoring systems have been proposed but have not performed consistently[3-6]. For example, El-Solh[3] tested 4 prognostic models constructed to predict in-hospital mortality for SARS-CoV-2 patients; proposed by Chen *et al*[7], Shang *et al*[8], Yu *et al*[9], and Wang *et al*[10]. All models had been peer-reviewed and were based on a cohort size of ≥100. All the models examined had validation area under curves (AUCs), which were significantly worse than the area under curves of their derivation cohorts. For example, the AUC of the validation cohort using the model proposed by Chen *et al*[7] was at best 0.69 (95% confidence interval [CI] 0.66-0.72) compared to the derivation AUC, which was 0.91 (95% CI 0.85-0.97). A similar pattern was noted in the other 3 models.

Gupta[4] tested 20 candidate prognostic models using data derived from 411 consecutively admitted adults with a PCR-confirmed diagnosis of SARS-CoV-2 in a major London hospital. Five of these models were pre-existing point-based scores not specific for Covid19 (MEWS, REMS, qSOFA, CURB65 and NEWS2) and the remainder of which were a combination of point-based scores and logistic regression models specifically derived from SARS-CoV-2 patients. None of these methods overlapped with those previously tested by El-Solh and 9 of the 15 Covid-specific models had been developed in China. The most discriminating univariable predictor for in-hospital mortality was age (AUC 0.76 [95% CI 0.71-0.81]) and for in-hospital deterioration was oxygen saturation on room air (AUC 0.76 [95% CI 0.71-0.81]). More importantly, none of the models tested performed consistently better than these univariable predictors.

These inconsistencies are an ongoing issue. Bradley[6] concluded that the overall prognostic performance of established clinical scores (CURB-65, NEWS2 and qSOFA) was generally poor with reference to SARS-CoV-2, while Fan[11] concluded the opposite. To illustrate the AUC for CURB65 prognostic score was 0.85 (Fan[11]), 0.75 (Bradley[6]) and 0.698 (Kodama[12]). This begs the question - why are prognostic scores performing so inconsistently even when tested against cohorts who are similar clinically? We ran these meta-analyses to uncover possible reasons for these inconsistencies. As a secondary goal, we also sought an easily measurable, dependable single-parameter biomarker to predict mortality in swab-positive SARS-CoV-2 patients; especially as there is not always time or resources available to calculate a full prognostic model[13].

Methods

Data collection

We searched the PubMed database for the keywords 'SARS-CoV-2' in combination with 'biomarker name' and 'mortality'. The period for the first data tranche was set from the emergence of the SARS-CoV-2 pathogen on the 01st December 2019 to 30th June 2021. Two independent reviewers analyzed studies for relevance. All papers reporting mortality data for hospitalized patients swab-positive for SARS-CoV-2 with a biomarker level at presentation (0-48h of admission) were examined for a Receiver Operating Characteristic (ROC) analysis and a corresponding Area under Curve (AUC). When studies failed to quote the margin of error for AUCs, corresponding authors were contacted and their AUC data was included in pooled AUCs if confidence intervals or standard deviations were forthcoming. All studies are displayed in summary figures for completeness. Ethical approval was obtained from the Integrated Research Application System (reference 281880) for analysis of the Cambridge (UK) data. To ensure biomarkers were applicable to acute adult general admissions, we excluded reports of patients already admitted to intensive care or restricted to specific groups (pregnancy, hemodialysis, or transplant patients). Mortality (30-day or in-hospital) was used as the endpoint. The following data was collected from the root studies: a) Area under curve and 95% confidence intervals for the biomarkers examined (admission D-dimer, CRP, IL-6, troponin, urea); b) age of cohort (mean and standard deviation) and number of patients in cohort; c) geographical location of cohort (if a multi-center study, the location of the hospital of the first author was used). Europe/North America and Asia were the sources of most studies and were therefore the focus

of subsequent meta-analyses. This process is summarized in a PRISMA flowsheet depicted in Fig.1. This study is registered with PROSPERO with the CRD42022366893.

To determine the impact of multiple rounds of vaccination and new variants in the SARS-CoV-2 virus, we subsequently repeated the search using the PubMed database from 01st December 2019 to 31st March 2023 using the following combinations of keywords:

a) 'SARS-CoV-2' in combination with 'vaccination' and 'biomarker name'
b) 'SARS-CoV-2' in combination with 'variant' and 'biomarker name'
c) 'Covid19' in combination with 'vaccination' and 'biomarker name'
d) 'Covid19' in combination with 'variant' and 'biomarker name'

The results were then aggregated and individual papers were checked for a Receiver Operating Characteristic (ROC) analysis and a corresponding Area under Curve (AUC) with respect to a vaccinated cohort or to a proven or very likely variant. As there were very few papers with these data (n<5), we have elected not to perform any analyses but have displayed the raw data in Fig.5 and Table 2. A more detailed explanation is available in the online Supplement.

Statistical analysis

We have used area under curve (AUC) of the Receiver Operating Characteristic as the different studies we examined used different methods of biomarker analyses and/or presented data in

different units of measurement and, hence, were not directly comparable. Also, studies reported biomarker efficacies differently - for example, as odds ratios per unit increase (such as per ng/ml), odds ratio per block unit increase (such as per 5ng/ml) or by dividing at the median and comparing the top half with the bottom half. We needed a simple, reproducible estimate of efficacy that would discount the different methods and units of measurement and the AUC fulfilled this requirement.

To aggregate the data on age and biomarkers from individual studies, the *meta* library in R was used to report overall mean values and 95% confidence intervals and the statistical significance of differences between mean values in the joint European and North American cohort and the Asian cohort. This analysis was based on estimates of standard errors for each study, obtained by assuming values for individual subjects were normally distributed in each study with a study-specific mean. In this way, measures of spread (IQR, SD and range) were converted into estimates of within-study standard deviations. Since the estimates of the study-specific means exhibited high levels of heterogeneity within both categories, a *random effects model* was fitted as opposed to a fixed effects model in the meta-analysis.

Sensitivity analyses

Sensitivity analyses were performed by serially excluding each study to determine the implications of individual studies on the pooled AUC. No individual study had a significant implication for pooled AUCs for either European/North American or the Asian cohorts

(Supplementary Tables 1-5). Note that when fitting a random effects meta-analysis model, the individual study means are assumed to be random, and the between-study heterogeneity (tau^2) needs to be estimated. For the pooled AUC, we used a single estimate of tau^2 based on the overall dataset (both European/North American and the Asian studies) due to small sample sizes, so removing a study affects this and thereby may shift the confidence intervals very slightly for the other subgroup.

Patient and public involvement

We discussed how best to display our data and results with the members of the public and patients. Following this, we have created a free-to-access, publicly-available website (https://covid19.cimr.cam.ac.uk/), with a map displaying the source data and links back to the original studies. Root study authors have also volunteered that statistical software is expensive and hence inaccessible. Therefore, we have written a programme in R that allows for the calculation of the AUC of a biomarker which is free to download from the same website. Our intention is that everyone will be able to view the most effective biomarkers for their locale from the website and to calculate an AUC for their own data. Volunteers have also tested the website and software for accessibility and ease of use.

Results

Initially we examined 1,930 articles that were published from the beginning of the SARS-CoV-2 pandemic in 01st December 2019 to 30th June 2021, and selected 131 papers that met our pre-specified selection criteria. This process is summarized in Fig.1 and all reference papers are listed in the References (Meta-analyses) section.

Our meta-analyses have revealed differences in the effectiveness of biomarkers in different regions of the world. These are summarized in Fig.2. For example, admission CRP levels are a good prognostic marker for mortality in Asian countries, with a pooled AUC (area under curve) of 0.83 (95% CI 0.80-0.85) from 34 studies, but only an average predictor of mortality in Europe and North America, with a pooled AUC of 0.67 (95% CI 0.63-0.71) from 21 studies ($P<0.0001$, Fig.3A, Table 1). We see the same pattern for admission D-dimer and IL-6 levels – they are good predictors of mortality in Asian countries (pooled AUCs of 0.78 [95% CI 0.76-0.82]) and 0.86 [95% CI 0.81-0.90] respectively) but not in Europe and North America (pooled AUCs of 0.69 [95% CI 0.66-0.72] and 0.70 [95% CI 0.64-0.75] respectively; $P<0.0001$ for both compared to Asian counterparts; Fig.3B and Fig.4A). This explains why the prognostic scores that are being proposed for SARS-CoV-2 do not perform evenly in different countries, as the 'building blocks' underpinning these prognostic scores have intrinsically different effectiveness in different populations.

There are two biomarkers that performed well in all cohorts regardless of geographical location. Admission troponin levels had a pooled AUC of 0.81 [95% CI 0.77-0.85] in Asian

countries and a pooled AUC of 0.79 [95% CI 0.74-0.83] in European and North American countries (Fig.4B). Similarly, urea levels on admission had a pooled AUC of 0.79 [95% CI 0.70-0.85] in Asian countries and a pooled AUC of 0.78 [95% CI 0.74-0.81] in European and North American countries (Fig.4C). This implies that end-organ damage at the time of presentation is a key prognostic indicator of severity for SARS-CoV-2.

It was noted very early on that the elderly fared worse in this pandemic. Therefore, it was reasonable to evaluate whether age itself was a reasonable predictor of mortality, given that this is usually instantaneously available directly from the patient. Interestingly, in the Asian cohorts, age fared less well when compared to all 5 biomarkers examined (Table 1, Fig.2). The exact opposite was seen in the European/North American cohorts, with age (AUC 0.78 [95% CI 0.77-0.80]) outperforming the inflammatory biomarkers (D-dimer, CRP, and IL-6) and being equivalent to the biomarkers showing end-organ damage (urea and troponin).

Pooling all the results from Asian, European, and North American studies gave a false impression of overall effectiveness for CRP, D-dimer, and IL-6 (Table 1). As an example, the pooled AUC for CRP for the entire dataset is 0.78 (95% CI 0.74-0.81). When separated into the regional blocks as previously described it becomes obvious that the Asian studies are skewing the results and masking the fact that admission levels of CRP, D-dimer and IL-6 are simply not very effective in predicting mortality in European and North American countries.

We expected that multiple rounds of vaccinations and ongoing mutations into different strains would significantly impact biomarker efficacy. Therefore, further analyses were conducted to examine this in further detail. There was a paucity of studies where information on vaccination status and viral variant was available, and we could only find 4 studies with sufficient numbers to conduct mortality analyses, which were relevant (Table 2 and Fig.5). It appears that in both the N. American/European and Asian cohorts that the efficacy of D-dimer and CRP as a biomarker for mortality is declining in the vaccinated *versus* the unvaccinated groups. This 'blunting' effect is also observed in the Delta and Omicron waves compared to the original data (Table 2).

Discussion

SARS-CoV-2 represented an unprecedented challenge to the medical, financial, and social frameworks of countries around the world. At the same time, the pandemic has triggered rapid and significant advances in medical technology, including but not limited to messenger RNA vaccines, pragmatic multi-armed trials of interventions, and large-scale production and use of lateral flow testing. From our point of view, SARS-CoV-2 has offered an opportunity to test biomarkers on a worldwide scale; as it is a single clearly defined clinical entity (*e.g.* by PCR-positivity or lack thereof), and a huge amount of data (including mortality data) was available in a very short timeframe from multiple countries.

Therefore we are able to demonstrate what we have long suspected - that biomarker effectiveness for mortality in SARS-CoV-2 varies significantly by geographical location. This important finding has an impact for clinicians using biomarkers and/or prognostic scores derived in other regions to assist the process of decision-making (e.g. whether to admit to intensive care) particularly when 'waves' of infection risk overwhelming local health resources. Consistent with our findings, Marino *et al*[14] demonstrated that a prognostic score developed in the same country (PREDI-CO, Bartoletti et al[15], Italy) had reasonable predictive power (AUC of 0.76, 95% CI 0.58-0.93) while a prognostic score developed in another country (Yan-XGBoost, Yan *et al*[16], China) did not perform satisfactorily (AUC of 0.57, 95% CI 0.37-0.76) when applied to their cohort.

This likely applies to other conditions. CURB-65 is well-known and validated as a tool for predicting mortality in community-acquired pneumonia[17], developed in the UK, New Zealand, and the Netherlands. However, it performs less satisfactorily in older populations[18]. For example, Shirata *et al*[19] demonstrated that CURB-65 had an AUC of 0.672 (95% CI 0.607-0.732) when applied to patients ≥65 years. Since Japan has one of the world's highest life expectancies, it is likely that CURB-65 would not perform as well if applied to a Japanese cohort. Interestingly, CURB-65 also performs poorly when applied to Colombian patients (AUCs of 0.629-0.669 when tested against 3 cohorts)[20]. Hincapie suggested that this may be due to the factors underpinning a significant difference in community-acquired pneumonia-associated mortality (9.5%[17] *versus* 17-32%[20]). Although it has been suspected that this is the case, we note that biomarkers and prognostic scores developed in large multi-center trials in

predominantly developed countries continue to be used in other countries and be incorporated into national guidelines without prior validation. Therefore, we suggest that prognostic biomarkers and scores must be explicitly validated before being used in novel populations. To make this easier, it might be reasonable to suggest that standardized documents for collecting information for the purpose of biomarker validation (such as in the form of downloadable online supplements) be provided by the authors whenever a new biomarker or score is proposed. Then the original manuscript could be updated easily (online) to state that such a score has now been validated in a particular country or target population.

It is not possible to know from these descriptive meta-analyses why there are these regional differences in biomarker effectiveness. The differences might be due to cohort age, different modes of death, genetic backgrounds, treatment effects, and/or various combinations of the above. The Asian cohorts were universally younger than the European/North American cohorts in all five parameters we investigated (CRP, D-dimer, troponin, urea, and IL-6; Table 1). It is possible that younger patients in Asia were dying from cytokine storm (hence the marked prognostic value of the 'inflammatory' markers such as CRP, D-dimer, and IL-6), while older people were dying from multi-organ failure in Europe. It is also possible that there has been a 'training effect', with the West having had prior warning from the Asian experience. The earlier use of specific anti-inflammatory approaches, in particular steroids and tocilizumab, has most probably blunted the effectiveness of markers such as IL-6 and CRP as predictors of death. Social contact-limiting measures ('lockdowns') have likely changed the composition of people falling ill and hence seeking hospital admission.

Our initial study has some limitations that need to be stressed. First, a significant number of studies did not quote 95% confidence intervals (14 of 78 for D-dimer, 18 of 75 for CRP, 3 of 35 for troponin, 1 of 16 for urea, 8 of 38 for IL-6), and we were unable to obtain them despite best efforts to communicate with the authors. These studies are included in Figs.3-4 but are not included in the calculation of the pooled AUCs. Second, insufficient numbers of studies were located in other continents to perform an adequate meta-analysis. Third, the majority of studies in the Asian section were from China (so 34 of 47 studies for CRP were on the Chinese population), and so the result may be representative of the Chinese population rather than of Asian populations in general. Finally, due to the nature of our representative characteristic, we are unable to suggest threshold values for the biomarkers in question.

The other important point we would like to make is that we were woefully underprepared for a health emergency on this scale. Most of the data we have shown is pertinent to the initial viral lineages, and by the time the meta-analyses were performed, novel lineages of clinical relevance, such as Alpha, Delta, and Omicron, have emerged. Moreover, one should note that the area under the curve may not give a complete picture of biomarker efficacy, and there are other measures that could be alternatively applied, e.g., relative risk increase per unit increase of a biomarker, relative risk increase compared to the lower 50%.

The key then lies in being prepared in the case of future threats. We propose that information frameworks be set up ahead of time, and then clinicians and scientists can simply 'slot in' their data as it becomes available, such as on a freely accessible website that is publicly available in real-time or as close to that as possible. It may also be wise to have designated centres and staff who will act to provide such data. For example, we mapped the root studies on the following website (https://covid19.cimr.cam.ac.uk/) and wrote a free-to-use software program that the healthcare community can use to check whether their biomarker of choice is effective in their population. Given that medical and research staff are likely to be incredibly busy if another pandemic strikes, it would make sense to make sure that as much of the process is as automated as possible*, e.g.* by using dedicated programmes to automatically harvest demographics, biomarkers, and mortality data from medical software administration systems where these are in use. It could be agreed beforehand what data is needed, and this could be set out in modular stages. For example, basic requirements could be age, sex, biomarker(s) levels, and outcome, while secondary outcomes (such as imaging data, complications, and long-term sequelae) could be 'bolt-on' options. Furthermore, specific centres could be designated to collect data from specific groups, e.g. pregnant women, children, and immunocompromised people. In this way, data collection can be standardized and organized rather than growing organically as was the case in SARS-CoV-2. The availability of such data would not just aid in biomarker identification but also allow the rapid organization of clinical trials by pinpointing 'at-risk' groups early who could be targeted for vaccination or intervention programmes. Planning ahead would also allow the ethical permissions for gathering and analysing such data to be applied for and granted beforehand; and for public opinion to be sought in how data can be

used while protecting the confidentiality of individual patients. A good analogy would be preparing for disasters such as earthquakes or fires – plans for these are now accepted as a mandatory part of keeping people safe around the world.

There are drawbacks associated with this approach. Firstly, these steps may only be possible in countries with the funding and resources to undertake them. We note that even now there still is very little data regarding SARS-CoV-2 from less-developed countries. We would urge large health and charitable organisations such as the World Health Organisation to pinpoint this as an area requiring further funding and development, ideally before another pandemic. Second, there would have to be international agreements regarding the use and protection of patient data. There will also be much commercial interest in this kind of data, particularly for the development of vaccines and treatments, and there should be protocols to protect data-harvesting/selling without commensurate benefit to patients who have provided the data.

In short, the SARS-CoV-2 pandemic exerted a terrible toll worldwide. We owe it to ourselves and to future generations to learn from this experience. The principle take-home messages are that biomarkers should be tailored to and validated in their target populations; and that we need to be prepared for rapid information gathering and analyses ahead of another pandemic.

References (body of manuscript):

1. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* 2021;19(3):141-54. doi: 10.1038/s41579-020-00459-7 [published Online First: 2020/10/08]

2. Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. *PLoS One* 2020;15(11):e0241536. doi: 10.1371/journal.pone.0241536 [published Online First: 2020/11/04]

3. Bak A, Mugglestone MA, Ratnaraja NV, et al. SARS-CoV-2 routes of transmission and recommendations for preventing acquisition: joint British Infection Association (BIA), Healthcare Infection Society (HIS), Infection Prevention Society (IPS) and Royal College of Pathologists (RCPath) guidance. *J Hosp Infect* 2021;114:79-103. doi: 10.1016/j.jhin.2021.04.027 [published Online First: 2021/05/04]

4. El-Solh AA, Lawson Y, Carter M, et al. Comparison of in-hospital mortality risk prediction models from COVID-19. *PLoS One* 2020;15(12):e0244629. doi: 10.1371/journal.pone.0244629 [published Online First: 2020/12/29]

5. Gupta RK, Marks M, Samuels THA, et al. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. *Eur Respir J* 2020;56(6) doi: 10.1183/13993003.03498-2020 [published Online First: 2020/09/27]

6. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of

the 4C Mortality Score. *Bmj* 2020;370:m3339. doi: 10.1136/bmj.m3339 [published Online First: 2020/09/11]

7. Bradley P, Frost F, Tharmaratnam K, et al. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. *BMJ Open Respir Res* 2020;7(1) doi: 10.1136/bmjresp-2020-000729

8. Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest* 2020;158(1):97-105. doi: 10.1016/j.chest.2020.04.010 [published Online First: 2020/04/19]

9. Shang Y, Liu T, Wei Y, et al. Scoring systems for predicting mortality for severe patients with COVID-19. *EClinicalMedicine* 2020;24:100426. doi: 10.1016/j.eclinm.2020.100426 [published Online First: 2020/08/09]

10. Yu C, Lei Q, Li W, et al. Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China. *Am J Prev Med* 2020;59(2):168-75. doi: 10.1016/j.amepre.2020.05.002 [published Online First: 2020/06/23]

11. Wang K, Zuo P, Liu Y, et al. Clinical and Laboratory Predictors of In-hospital Mortality in Patients With Coronavirus Disease-2019: A Cohort Study in Wuhan, China. *Clin Infect Dis* 2020;71(16):2079-88. doi: 10.1093/cid/ciaa538 [published Online First: 2020/05/04]

12. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. *Eur Respir J* 2020;56(3) doi: 10.1183/13993003.02113-2020 [published Online First: 20200910]

13. Kodama T, Obinata H, Mori H, et al. Prediction of an increase in oxygen requirement of SARS-CoV-2 pneumonia using three different scoring systems. *J Infect Chemother* 2021;27(2):336-41. doi: 10.1016/j.jiac.2020.12.009 [published Online First: 2021/01/07]

14. Schultz MJ, Gebremariam TH, Park C, et al. Pragmatic Recommendations for the Use of Diagnostic Testing and Prognostic Models in Hospitalized Patients with Severe COVID-19 in Low- and Middle-Income Countries. *Am J Trop Med Hyg* 2021;104(3_Suppl):34-47. doi: 10.4269/ajtmh.20-0730 [published Online First: 2021/02/04]

15. Marino L, Suppa M, Rosa A, et al. Time to hospitalisation, CT pulmonary involvement and in-hospital death in COVID-19 patients in an Emergency Medicine Unit. *Int J Clin Pract* 2021;75(9):e14426. doi: 10.1111/ijcp.14426 [published Online First: 20210616]

16. Bartoletti M, Giannella M, Scudeller L, et al. Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). *Clin Microbiol Infect* 2020;26(11):1545-53. doi: 10.1016/j.cmi.2020.08.003 [published Online First: 20200808]

17. Yan L, Zhang H-T, Goncalves J, et al. An interpretable mortality prediction model for COVID-19 patients. *Nature Machine Intelligence* 2020;2(5):283-88. doi: 10.1038/s42256-020-0180-7

18. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58(5):377-82. doi: 10.1136/thorax.58.5.377

19. Parsonage M, Nathwani D, Davey P, et al. Evaluation of the performance of CURB-65 with increasing age. *Clin Microbiol Infect* 2009;15(9):858-64. doi: 10.1111/j.1469-0691.2009.02908.x

20. Shirata M, Ito I, Ishida T, et al. Development and validation of a new scoring system for prognostic prediction of community-acquired pneumonia in older adults. *Sci Rep* 2021;11(1):23878. doi: 10.1038/s41598-021-03440-3 [published Online First: 20211213]

21. Hincapié C, Ascuntar J, León A, et al. Community-acquired pneumonia: comparison of three mortality prediction scores in the emergency department. *Colomb Med (Cali)* 2021;52(4):e2044287. doi: 10.25100/cm.v52i4.4287 [published Online First: 20211023]

Biomarker	Location	Pooled AUC	95% CI	*P*-value AUC	Mean age	*P*-value age	No. of patients	No. of studies
D-dimer	Asia	0.78	0.76-0.82	<0.00001	57.9	<0.00001	14,076	38
	Europe/ N. America	0.69	0.66-0.72		64.6		29,741	22
	All	**0.76**	**0.73-0.78**					
CRP	Asia	0.83	0.80-0.85	<0.00001	57.8	<0.00001	10,407	34
	Europe/ N. America	0.67	0.63-0.71		64.8		28,693	21
	All	**0.78**	**0.74-0.81**					
Urea	Asia	0.79	0.70-0.85	0.86	60.6	0.027	3,123	10
	Europe/ N. America	0.78	0.74-0.81		66.1		2,880	6
	All	**0.77**	**0.72-0.82**					
Troponin	Asia	0.81	0.77-0.85	0.42	61.1	0.011	7,308	16
	Europe/ N. America	0.79	0.74-0.83		65		8,690	16
	All	**0.8**	**0.77-0.83**					
IL-6	Asia	0.86	0.81-0.90	<0.00001	58.2	0.033	2,993	17
	Europe/ N. America	0.7	0.64-0.75		63.5		6,362	20
	All	**0.78**	**0.73-0.83**					
Age	Asia	0.73	0.65-0.79	0.0408	57.3	0.028	2,652	9
	Europe/ N. America	0.78	0.77-0.80		62.9		18,127	5
	All	**0.75**	**0.70-0.90**					

Table 1: Summary of pooled area under curves and mean ages (+/-SD) for the 5 biomarkers investigated for the initial analyses (2020-end of June 2021).

AUC: area under curve

CI: confidence interval

SD : standard deviation

IL-6: interleukin-6

CRP: C-reactive protein

Source Country	Parameter	2020-mid-2021 Pooled AUC	2020	2021	2022
			B.1.338	***Delta***	***Omicron***
Wang Australia	AUC CRP all-cause mortality	0.67 (0.63-0.71)*	0.6 (0.49, 0.70)	0.55 (0.46, 0.64)	0.61 (0.51, 0.70)
	AUC CRP non-vaccinated	N/A	N/A	0.58 (0.49, 0.68)	0.61 (0.45, 0.78)
	AUC CRP fully vaccinated	N/A	N/A	N/A	0.57 (0.44, 0.69)
	AUC D-dimer all-cause mortality	0.69 (0.66-0.72)*	0.69 (0.56, 0.82)	0.69 (0.59, 0.78)	0.63 (0.52, 0.73)
	AUC D-dimer non-vaccinated	N/A	N/A	0.69 (0.58, 0.79)	0.66 (0.47, 0.85)
	AUC D-dimer fully vaccinated	N/A	N/A	0.58 (0.14, 1.00)	0.57 (0.43, 0.72)
				Delta	
Rzymski Poland	AUC CRP fully vaccinated	0.67 (0.63-0.71)		0.675 (0.640 - 0.709)	
	AUC D-dimer fully vaccinated	0.69 (0.66-0.72)		0.649 (0.613 – 0.685)	
	AUC IL-6 fully vaccinated	0.7 (0.64-0.75)		0.738 (0.695 – 0.778)	
					Omicron
Patel India	AUC CRP non-vaccinated	0.83 (0.80-0.85)			0.627 (0.389-0.865)
	AUC CRP fully vaccinated	N/A			0.771 (0.653-0.889)
	AUC D-dimer non-vaccinated	0.78 (0.76-0.82)			0.868 (0.715-1.02)
	AUC D-dimer fully vaccinated	N/A			0.667 (0.471-0.868)
				Original/Alpha	
Altintop Turkey	AUC CRP non-vaccinated	0.83 (0.80-0.85)		0.668 (0.592-0.739)	
	AUC CRP fully vaccinated	N/A		0.715 (0.603-0.811)	

Table 2: Summary of studies with vaccinated cohorts and variant data for the 5 biomarkers investigated.

AUC: area under curve

IL-6: interleukin-6

CRP: C-reactive protein

The reference AUC has been displayed in a coloured font (red for Asian and blue for European/N.American so as to be consistent with the other figures in the manuscript).

*The European/N.American figures have been shown as a reference as approximately 90% of Australia's population has European ancestry.

Figure legends

Figure 1: PRISMA flow diagram for paper review, selection, and inclusion in these meta-analyses.

Figure 2: Summary forest plot demonstrating pooled area under curves for the five biomarkers being meta-analyzed (CRP, D-dimer, troponin, urea, and IL-6) and age. For ease of comparison values for Asian countries are shown in red and values for European/North American countries are shown in blue. There was insufficient data to accurately construct pooled AUCs for other geographical regions.

Figure 3: Forest plot demonstrating all individual studies contributing to the meta-analyses for (A) CRP and (B) D-dimer in Asian and European/North American countries for the first tranche of data (from Jan 2020 – June 2021).

Blue diamond: pooled AUC for European/North American countries

Red diamond: pooled AUC for Asian countries

The size of each square representing an individual study corresponds with the size of the study population:

Font 4: 0-100

Font 5: 100-1,000

Font 6: 1,001-10,000

Font 7: >10,001



For the reader's ease the data sources are arranged alphabetically both within the figure and in the references (meta-analyses) sections.

Figure 4: Forest plot demonstrating all individual studies contributing to the meta-analyses for (A) IL-6, (B) urea (C) troponin, and (D) age in Asian and European/North American countries for the first tranche of data (from Jan 2020 – June 2021).

Blue diamond: pooled AUC for European/North American countries

Red diamond: pooled AUC for Asian countries

The size of each square representing an individual study corresponds with the size of the study population:

Font 4: 0-100

Font 5: 100-1,000

Font 6: 1,001-10,000

Font 7: >10,001



For the reader's ease, the data sources are arranged alphabetically both within the figure and in the references (meta-analyses) sections.

Figure 5: Forest plot demonstrating all individual studies with data relating to a vaccinated cohort or to a cohort with a known variant.

Blue diamond: pooled AUC for European/North American countries

Red diamond: pooled AUC for Asian countries

The size of each square representing an individual study corresponds with the size of the study population:

Font 4: 0-100

Font 5: 100-1,000

Font 6: 1,001-10,000

Font 7: >10,001



References (Meta-analyses)

1. **Aksel G**, İslam MM, Algın A, Eroğlu SE, Yaşar GB, Ademoğlu E, Dölek Ü C. Early predictors of mortality for moderate to severely ill patients with Covid-19. *Am J Emerg Med* 2021; 45: 290-296.

2. **Aloisio E**, Chibireva M, Serafini L, Pasqualetti S, Falvella FS, Dolci A, Panteghini M. A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. *Arch Pathol Lab Med* 2020; 144: 1457-1464.

3. **Altintop SE**, Unalan-Altintop T, Cihangiroglu M, Onarer P, Milletli-Sezgin F, Gozukara M, Gozukara B, Zengin E. COVID-19 in elderly: Correlations of viral load, clinical course, laboratory parameters, among patients vaccinated with CoronaVac. Acta Microbiol Immunol Hung. 2022 Nov 11;69(4):277-282.

4. **Antunez Muiños PJ**, López Otero D, Amat-Santos IJ, López País J, Aparisi A, Cacho Antonio CE, Catalá P, González Ferrero T, Cabezón G, Otero García O, Gil JF, Pérez Poza M, Candela J, Rojas G, Jiménez Ramos V, Veras C, San Román JA, González-Juanatey JR. The COVID-19 lab score: an accurate dynamic tool to predict in-hospital outcomes in COVID-19 patients. *Sci Rep* 2021; 11: 9361.

4. **Asghar MS**, Haider Kazmi SJ, Khan NA, Akram M, Hassan M, Rasheed U, Ahmed Khan S. Poor Prognostic Biochemical Markers Predicting Fatalities Caused by COVID-19: A Retrospective Observational Study From a Developing Country. *Cureus* 2020; 12: e9575.

5. **Bastug A**, Bodur H, Erdogan S, Gokcinar D, Kazancioglu S, Kosovali BD, Ozbay BO, Gok G, Turan IO, Yilmaz G, Gonen CC, Yilmaz FM. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. *Int Immunopharmacol* 2020; 88: 106950.

6. **Bilgir F**, Çalık Ş, Demir İ, Bilgir O. Roles of certain biochemical and hematological parameters in predicting mortality and ICU admission in COVID-19 patients. *Rev Assoc Med Bras (1992)* 2021; 67Suppl 1: 67-73.

7. **Bintoro SUY**, Dwijayanti NMI, Pramudya D, Amrita PN, Romadhon PZ, Asmarawati TP, Bachtiar A, Hadi U. Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia. *F1000Res* 2021; 10: 791.

8. **Cao J**, Zheng Y, Luo Z, Mei Z, Yao Y, Liu Z, Liang C, Yang H, Song Y, Yu K, Gao Y, Zhu C, Huang Z, Qian J, Ge J. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. *Theranostics* 2020; 10: 9663-9673.

9. **Carlino MV**, Valenti N, Cesaro F, Costanzo A, Cristiano G, Guarino M, Sforza A. Predictors of Intensive Care Unit admission in patients with coronavirus disease 2019 (COVID-19). *Monaldi Arch Chest Dis* 2020; 90.

10. **Chen FF**, Zhong M, Liu Y, Zhang Y, Zhang K, Su DZ, Meng X, Zhang Y. The characteristics and outcomes of 681 severe cases with COVID-19 in China. *J Crit Care* 2020; 60: 32-37.

11. **Chen H**, Li X, Marmar T, Xu Q, Tu J, Li T, Han J, Xu D, Shen T. Cardiac Troponin I association with critical illness and death risk in 726 seriously ill COVID-19 patients: A retrospective cohort study. *Int J Med Sci* 2021; 18: 1474-1483.

12. **Chen L**, Hu W, Guo X, Zhao P, Tang J, Gu Y, Huang N, Wang C, Cui A, Zhang D, Hu L, Feng Y, Hu S, Chen M, Duru F, Xiong C. Association of coagulation dysfunction with cardiac injury among hospitalized patients with COVID-19. *Sci Rep* 2021; 11: 4432.

13. **Chen X**, Wang Q, Xu M, Li C. A Retrospective Analysis of the Coagulation Dysfunction in COVID-19 Patients. *Clin Appl Thromb Hemost* 2020; 26: 1076029620964868.

14. **Cheng A**, Hu L, Wang Y, Huang L, Zhao L, Zhang C, Liu X, Xu R, Liu F, Li J, Ye D, Wang T, Lv Y, Liu Q. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. *Int J Antimicrob Agents* 2020; 56: 106110.

15. **Cheng B**, Hu J, Zuo X, Chen J, Li X, Chen Y, Yang G, Shi X, Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. *Clin Microbiol Infect* 2020; 26: 1400-1405.

16. **Cheng S**, Wu D, Li J, Zou Y, Wan Y, Shen L, Zhu L, Shi M, Hou L, Xu T, Jiao N, Li Y, Huang Y, Tang Z, Xu M, Jiang S, Li M, Yan G, Lan P, Zhu R. Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study. *Respir Res* 2020; 21: 277.

17. **Chocron R**, Duceau B, Gendron N, Ezzouhairi N, Khider L, Trimaille A, Goudot G, Weizman O, Alsac JM, Pommier T, Bory O, Cellier J, Philippe A, Geneste L, Ben Abdallah I, Panagides V, El Batti S, Marsou W, Juvin P, Deney A, Messas E, Attou S, Planquette B, Mika D, Gaussem P, Fauvel C, Diehl JL, Pezel T, Mirault T, Sutter W, Sanchez O, Bonnet G, Cohen A, Smadja DM. D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. *Arch Cardiovasc Dis* 2021.

18. **Cipriani A**, Capone F, Donato F, Molinari L, Ceccato D, Saller A, Previato L, Pesavento R, Sarais C, Fioretto P, Iliceto S, Gregori D, Avogaro A, Vettor R. Cardiac injury and mortality

in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. *Intern Emerg Med* 2021; 16: 419-427.

19. **Creel-Bulos C**, Liu M, Auld SC, Gaddh M, Kempton CL, Sharifpour M, Sniecinski RM, Maier CL, Nahab FB, Rangaraju S. Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. *Medicine (Baltimore)* 2020; 99: e23186.
20. **De Michieli L**, Babuin L, Vigolo S, Berti De Marinis G, Lunardon A, Favretto F, Lobo R, Sandoval Y, Bryant SC, Donato D, Plebani M, Vettor R, Iliceto S, Cianci V, Jaffe AS. Using high sensitivity cardiac troponin values in patients with SARS-CoV-2 infection (COVID-19): The Padova experience. *Clin Biochem* 2021; 90: 8-14.
21. **Deng P**, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. *Clin Chim Acta* 2020; 510: 186-190.
22. **Dolci A**, Robbiano C, Aloisio E, Chibireva M, Serafini L, Falvella FS, Pasqualetti S, Panteghini M. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. *Clin Chem Lab Med* 2020; 59: 433-440.
23. **Donoso-Navarro E**, Arribas Gómez I, Bernabeu-Andreu FA. IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid. *Biomark Insights* 2021; 16: 11772719211013363.
24. **Duan J**, Wang X, Chi J, Chen H, Bai L, Hu Q, Han X, Hu W, Zhu L, Wang X, Li Y, Zhou C, Mou H, Yan X, Guo S. Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing. *J Med Virol* 2020; 92: 2616-2622.

25. **Fu J**, Kong J, Wang W, Wu M, Yao L, Wang Z, Jin J, Wu D, Yu X. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb Res* 2020; 192: 3-8.

26. **Gao Y**, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol* 2020; 92: 791-796.

27. **Gatti M**, Calandri M, Biondo A, Geninatti C, Piatti C, Ruggirello I, Santonocito A, Varello S, Bergamasco L, Bironzo P, Boccuzzi A, Brazzi L, Caironi P, Cardinale L, Cavallo R, Riccardini F, Limerutti G, Veltri A, Fonio P, Faletti R. Emergency room comprehensive assessment of demographic, radiological, laboratory and clinical data of patients with COVID-19: determination of its prognostic value for in-hospital mortality. *Intern Emerg Med* 2022; 17: 205-214.

28. **Gavin W**, Campbell E, Zaidi SA, Gavin N, Dbeibo L, Beeler C, Kuebler K, Abdel-Rahman A, Luetkemeyer M, Kara A. Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19. *Am J Infect Control* 2021; 49: 158-165.

29. **Genç AB**, Yaylacı S, Dheir H, Genç AC, İşsever K, Çekiç D, Kocayiğit H, Çokluk E, Karacan A, Şekeroğlu MR, Toptan Çakar H, Güçlü E. The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia. *Turk J Med Sci* 2021; 51: 448-453.

30. **Goudot G**, Chocron R, Augy JL, Gendron N, Khider L, Debuc B, Aissaoui N, Peron N, Hauw-Berlemont C, Vedie B, Cheng C, Mohamedi N, Krzisch D, Philippe A, Puscas T, Hermann B, Brichet J, Juvin P, Planquette B, Messas E, Pere H, Veyer D, Gaussem P, Sanchez O,

Diehl JL, Mirault T, Smadja DM. Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload. *Front Med (Lausanne)* 2020; 7: 586307.

31. **Gu Y**, Wang D, Chen C, Lu W, Liu H, Lv T, Song Y, Zhang F. PaO(2)/FiO(2) and IL-6 are risk factors of mortality for intensive care COVID-19 patients. *Sci Rep* 2021; 11: 7334.
32. **Guirao JJ**, Cabrera CM, Jiménez N, Rincón L, Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol* 2020; 128: 64-68.
33. **Güneysu F,** Guner NG, Erdem AF, Durmus E, Durgun Y, Yurumez Y. Can COVID-19 Mortality be Predicted in the Emergency Room? *J Coll Physicians Surg Pak* 2020; 30: 928-932.
34. **Han H**, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect* 2020; 9: 1123-1130.
35. **Harmouch F**, Shah K, Hippen JT, Kumar A, Goel H. Is it all in the heart? Myocardial injury as major predictor of mortality among hospitalized COVID-19 patients. *J Med Virol* 2021; 93: 973-982.
36. **He X**, Yao F, Chen J, Wang Y, Fang X, Lin X, Long H, Wang Q, Wu Q. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Sci Rep* 2021; 11: 1830.
37. **Herold T**, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol* 2020; 146: 128-136.e124.

38. **Huang Y**, Lyu X, Li D, Wang L, Wang Y, Zou W, Wei Y, Wu X. A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19. *PLoS One* 2020; 15: e0242045.

39. **Infante M**, Buoso A, Pieri M, Lupisella S, Nuccetelli M, Bernardini S, Fabbri A, Iannetta M, Andreoni M, Colizzi V, Morello M. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study. *J Am Coll Nutr* 2021: 1-16.

40. **Jin X**, Duan Y, Bao T, Gu J, Chen Y, Li Y, Mao S, Chen Y, Xie W. The values of coagulation function in COVID-19 patients. *PLoS One* 2020; 15: e0241329.

41. **Jøntvedt Jørgensen M**, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Grøndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. *Sci Rep* 2020; 10: 21697.

42. **Kaufmann CC**, Ahmed A, Kassem M, Freynhofer MK, Jäger B, Aicher G, Equiluz-Bruck S, Spiel AO, Funk GC, Gschwantler M, Fasching P, Wojta J, Huber K. Mid-regional pro-atrial natriuretic peptide independently predicts short-term mortality in COVID-19. *Eur J Clin Invest* 2021; 51: e13531.

43. **Ke C**, Yu C, Yue D, Zeng X, Hu Z, Yang C. Clinical characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study. *Med Clin (Engl Ed)* 2020; 155: 327-334.

44. **Keski H**. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. *Indian J Hematol Blood Transfus* 2021: 1-9.

45. **Korkusuz R**, Karandere F, Senoglu S, Kocoglu H, Yasar KK. The prognostic role of D-dimer in hospitalized COVID-19 patients. *Bratisl Lek Listy* 2021; 122: 811-815.

46. **Küçükceran K**, Ayranci MK, Girişgin AS, Koçak S. Predictive value of D-dimer/albumin ratio and fibrinogen/albumin ratio for in-hospital mortality in patients with COVID-19. *Int J Clin Pract* 2021: e14263.

47. **Laguna-Goya R**, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A, Naranjo L, Segura-Tudela A, Cabrera-Marante O, Rodriguez de Frias E, Garcia-Garcia R, Fernández-Ruiz M, Aguado JM, Martinez-Lopez J, Lopez EA, Catalan M, Serrano A, Paz-Artal E. IL-6-based mortality risk model for hospitalized patients with COVID-19. *J Allergy Clin Immunol* 2020; 146: 799-807.e799.

48. **Li J**, Wang L, Liu C, Wang Z, Lin Y, Dong X, Fan R. Exploration of prognostic factors for critical COVID-19 patients using a nomogram model. *Sci Rep* 2021; 11: 8192.

49. **Li Y**, Li H, Song C, Lu R, Zhao Y, Lin F, Han D, Chen L, Pan P, Dai M. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio. *Dis Markers* 2021; 2021: 6304189.

50. **Liang M**, He M, Tang J, He X, Liu Z, Feng S, Chen P, Li H, Xue Y, Bai T, Ma Y, Zhang J. Novel risk scoring system for predicting acute respiratory distress syndrome among hospitalized patients with coronavirus disease 2019 in Wuhan, China. *BMC Infect Dis* 2020; 20: 960.

51. **Liu F**, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; 127: 104370.

52. **Liu Q**, Song NC, Zheng ZK, Li JS, Li SK. Laboratory findings and a combined multifactorial approach to predict death in critically ill patients with COVID-19: a retrospective study. *Epidemiol Infect* 2020; 148: e129.

53. **Liu SL**, Wang SY, Sun YF, Jia QY, Yang CL, Cai PJ, Li JY, Wang L, Chen Y. Expressions of SAA, CRP, and FERR in different severities of COVID-19. *Eur Rev Med Pharmacol Sci* 2020; 24: 11386-11394.

54. **Long H**, Nie L, Xiang X, Li H, Zhang X, Fu X, Ren H, Liu W, Wang Q, Wu Q. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. *Biomed Res Int* 2020; 2020: 6159720.

55. **Luo HC**, You CY, Lu SW, Fu YQ. Characteristics of coagulation alteration in patients with COVID-19. *Ann Hematol* 2021; 100: 45-52.

56. **Luo X**, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B, Yang W. Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019. *Clin Infect Dis* 2020; 71: 2174-2179.

57. **Luo Y**, Xue Y, Mao L, Yuan X, Lin Q, Tang G, Song H, Wang F, Sun Z. Prealbumin as a Predictor of Prognosis in Patients With Coronavirus Disease 2019. *Front Med (Lausanne)* 2020; 7: 374.

58. **Macias-Muñoz L**, Wijngaard R, González-de la Presa B, Bedini JL, Morales-Ruiz M, Jiménez W. Value of clinical laboratory test for early prediction of mortality in patients with COVID-19: the BGM score. *J Circ Biomark* 2021; 10: 1-8.

59. **Maeda T**, Obata R, Rizk DD, Kuno T. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. *J Med Virol* 2021; 93: 463-471.

60. **Manocha KK**, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, Li HA, Lerman BB, Safford MM, Goyal P, Cheung JW. Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA(2)T(2) COVID-19 Mortality Risk Score. *J Am Heart Assoc* 2021; 10: e018477.

61. **Miki S**, Sasaki H, Horiuchi H, Miyata N, Yoshimura Y, Miyazaki K, Matsumura T, Takahashi Y, Suzuki T, Matano T, Kawana-Tachikawa A, Tachikawa N. On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19. *PLoS One* 2021; 16: e0254640.

62. **Montrucchio G**, Sales G, Rumbolo F, Palmesino F, Fanelli V, Urbino R, et al. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study. PLoS One. 2021;16(2):e0246771.

63. **Mueller AA**, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell Rep Med. 2020;1(8):100144.

64. **Muhammad R**, Ogunti R, Ahmed B, Munawar M, Donaldson S, Sumon M, et al. Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. J Racial Ethn Health Disparities. 2021:1-11.

65. **Myhre PL**, Prebensen C, Strand H, Røysland R, Jonassen CM, Rangberg A, et al. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(22):2128-37.

66. **Nagant C**, Ponthieux F, Smet J, Dauby N, Doyen V, Besse-Hammer T, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis. 2020;101:342-5.

67. **Naymagon L**, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res. 2020;196:99-105.

68. **Okuyan HM**, Dogan S, Bal T, Çabalak M. Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19. Life Sci. 2021;278:119596.

69. **Oliva A**, Borrazzo C, Mascellino MT, Curtolo A, Al Ismail D, Cancelli F, et al. CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. Infez Med. 2021;29(3):408-15.

70. **Omland T**, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(19):1878-80.

71. **Otoshi R**, Hagiwara E, Kitayama T, Yamaya T, Higa K, Murohashi K, et al. Clinical characteristics of Japanese patients with moderate to severe COVID-19. J Infect Chemother. 2021;27(6):895-901.

72. **Ozdin M**, Yazar H, Yaylaci S, Koroglu M, Genc AC, Kocayigit İ, et al. Evaluation of cardiac parameters between survivors and nonsurvivors of COVID-19 patients. Rev Assoc Med Bras (1992). 2021;67Suppl 1(Suppl 1):80-5.

73. **Özyılmaz S**, Ergün Alış E, Ermiş E, Allahverdiyev S, Uçar H. Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). Medicina (Kaunas). 2020;56(12).

74. **Pan M**, Wang RR, Chen X, Han J, Li Q, Miao M, et al. Laboratory predictors of severe Coronavirus Disease 2019 and lung function in followed-up. Clin Respir J. 2021.

75. **Pascual Gómez NF**, Monge Lobo I, Granero Cremades I, Figuerola Tejerina A, Ramasco Rueda F, von Wernitz Teleki A, et al. [Potential biomarkers predictors of mortality in COVID-19 patients in the Emergency Department]. Rev Esp Quimioter. 2020;33(4):267-73.

76. **Patel AK**, Patel D, Shevkani M, Shah A, Madan S, Gohel S, Chhatwani C, Doshi A, Patel V, Sukhwani K, Kareliya H, Shah V, Savaj P, Rana M, Patel KK, Bakshi H. COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian J Med Microbiol. 2023 Jan-Feb;41:28-32.

77**. Peiró Ó M**, Carrasquer A, Sánchez-Gimenez R, Lal-Trehan N, Del-Moral-Ronda V, Bonet G, et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers. 2021;26(2):119-26.

78. **Petersen-Uribe A**, Avdiu A, Martus P, Witzel K, Jaeger P, Zdanyte M, et al. Impaired Myocardial Function Is Prognostic for Severe Respiratory Failure in the Course of COVID-19 Infection. Front Cardiovasc Med. 2021;8:584108.

79. **Pieri M**, Ciotti M, Nuccetelli M, Perrone MA, Caliò MT, Lia MS, et al. Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis. Int Immunopharmacol. 2021;95:107512.

80. **Poudel A**, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021;16(8):e0256744.

81. **Pouw N**, van de Maat J, Veerman K, Ten Oever J, Janssen N, Abbink E, et al. Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study. PLoS One. 2021;16(3):e0248713.

82. **Qeadan F**, Tingey B, Gu LY, Packard AH, Erdei E, Saeed AI. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. Viruses. 2021;13(3).

83. **Qin JJ**, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension. 2020;76(4):1104-12.

84. **Qin ZJ,** Liu L, Sun Q, Li X, Luo JF, Liu JS, et al. Impaired immune and coagulation systems may be early risk factors for COVID-19 patients: A retrospective study of 118 inpatients from Wuhan, China. Medicine (Baltimore). 2020;99(35):e21700.

85. **Quartuccio L**, Fabris M, Sonaglia A, Peghin M, Domenis R, Cifù A, et al. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and

hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. Cytokine. 2021;140:155438.

86. **Ramesh J**, Reddy SLS, Rajesh M, Varghese J. Evaluation of simple and cost-effective immuno- haematological markers to predict outcome in hospitalized severe COVID-19 patients, with a focus on diabetes mellitus - A retrospective study in Andhra Pradesh, India. Diabetes Metab Syndr. 2021;15(3):739-45.

87. **Rubio-Rivas M**, Corbella X, Formiga F, Menéndez Fernández E, Martín Escalante MD, Baños Fernández I, et al. Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry. J Clin Med. 2021;10(10).

88. **Ruscica M**, Macchi C, Iodice S, Tersalvi G, Rota I, Ghidini S, et al. Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience. Eur J Clin Invest. 2021;51(9):e13629.

89. **Rzymski P**, Pazgan-Simon M, Kamerys J, Moniuszko-Malinowska A, Sikorska K, Wernik J, Zarębska-Michaluk D, Supronowicz Ł, Sobala-Szczygieł B, Skrzat-Klapaczyńska A, Simon K, Piekarska A, Czupryna P, Pawłowska M, Brzdęk M, Jaroszewicz J, Kowalska J, Renke M, Flisiak R. Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. Vaccines (Basel). 2022 Apr 4;10(4):557. doi: 10.3390/vaccines10040557.

90. **Saji R**, Nishii M, Sakai K, Miyakawa K, Yamaoka Y, Ban T, et al. Combining IL-6 and SARS-CoV-2 RNAaemia-based risk stratification for fatal outcomes of COVID-19. PLoS One. 2021;16(8):e0256022.

91. **Salinas M**, Blasco Á, Santo-Quiles A, Lopez-Garrigos M, Flores E, Leiva-Salinas C. Laboratory parameters in patients with COVID-19 on first emergency admission is different in non-survivors: albumin and lactate dehydrogenase as risk factors. J Clin Pathol. 2020.

92. **Salvatici M**, Barbieri B, Cioffi SMG, Morenghi E, Leone FP, Maura F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. Biomarkers. 2020;25(8):634-40.

93. **Santa Cruz A**, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol. 2021;12:613422.

94. **Satış H,** Özger HS, Aysert Yıldız P, Hızel K, Gulbahar Ö, Erbaş G, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302.

95. **Selcuk M**, Cinar T, Gunay N, Keskin M, Cicek V, Kilic S, et al. Comparison of D-dimer Level Measured on the Third Day of Hospitalization with Admission D-dimer Level in Predicting In-hospital Mortality in COVID-19 Patients. Medeni Med J. 2021;36(1):1-6.

96. **Shang M**, Wei J, Zou HD, Zhou QS, Zhang YT, Wang CY. Early Warning Factors of Death in COVID-19 Patients. Curr Med Sci. 2021;41(1):69-76.

97. **Shang W**, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188-92.

98. **Sharif F**, Khan S, Junaid A, Jahangir S, Saeed M, Ijaz M, et al. Early hematological indicators of severe COVID-19 disease in hospitalized patients: Data from a South Asian population. Int J Lab Hematol. 2021.

99. **Shi S**, Nie B, Chen X, Cai Q, Lin C, Zhao G, et al. Clinical and laboratory characteristics of severe and non-severe patients with COVID-19: A retrospective cohort study in China. J Clin Lab Anal. 2021;35(1):e23692.

100. **Shi S**, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070-9.

101. **Shi X,** Qin L, Yang L, Bai W, Jing L, Mei K. [Value of interleukin-6 and CD4(+) T-lymphocytopenia in assessing the severity and prognosis of coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(10):1165-70.

102. **Smilowitz NR**, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-9.

103. **Soni M,** Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245-9.

104. Shuvo ME, Schwiening M, **Soares F**, Thompson R, Feng O, Samworth RJ, Morrell NW, Marciniak SJ, Thomas W, **Soon E**. Effectiveness of different parameters at admission as

prognostic markers for mortality due to SARS-CoV-2: a 2-centre experience in UK and Spain. Thorax 2021; 76 (Suppl 2): Axxvii.

105. **Sun W**, Zhang Y, Wu C, Xie Y, Peng L, Nie X, et al. Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients. Echocardiography. 2021;38(8):1272-81.

106. **Tahtasakal CA**, Oncul A, Sevgi DY, Celik E, Ocal M, Turkkan HM, et al. Could we predict the prognosis of the COVID-19 disease? J Med Virol. 2021;93(4):2420-30.

107. **Tang G**, Huang M, Luo Y, Liu W, Lin Q, Mao L, et al. The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. Front Immunol. 2021;12:697622.

109. **Turrini M**, Gardellini A, Beretta L, Buzzi L, Ferrario S, Vasile S, et al. Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy. Vaccines (Basel). 2021;9(6).

110. **van Dam** P, Zelis N, van Kuijk SMJ, Linkens A, Brüggemann RAG, Spaetgens B, et al. Performance of prediction models for short-term outcome in COVID-19 patients in the emergency department: a retrospective study. Ann Med. 2021;53(1):402-9.

111. **Villa E**, Critelli R, Lasagni S, Melegari A, Curatolo A, Celsa C, et al. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. Blood Adv. 2021;5(3):662-73.

112. **Vultaggio A**, Vivarelli E, Virgili G, Lucenteforte E, Bartoloni A, Nozzoli C, et al. Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients:

Usefulness of a Combined Score Using IL-6 in a Preliminary Study. J Allergy Clin Immunol Pract. 2020;8(8):2575-81.e2.

113. **Wang D**, Li R, Wang J, Jiang Q, Gao C, Yang J, et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect Dis. 2020;20(1):519.

114. **Wang F**, Hou H, Wang T, Luo Y, Tang G, Wu S, et al. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests. Travel Med Infect Dis. 2020;36:101782.

115. **Wang J**, Choy KW, Lim HY, Ho P. Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation? Intern Emerg Med. 2023 Jan;18(1):43-52.

116. **Wang M**, Zhu Q, Fu J, Liu L, Xiao M, Du Y. Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity. Infect Genet Evol. 2020;85:104511.

117. **Wang P**, Sha J, Meng M, Wang C, Yao Q, Zhang Z, et al. Risk factors for severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective study. J Transl Med. 2020;18(1):461.

118. **Wang Y**, Shu H, Liu H, Li X, Zhou X, Zou X, et al. The peak levels of highly sensitive troponin I predicts in-hospital mortality in COVID-19 patients with cardiac injury: a retrospective study. Eur Heart J Acute Cardiovasc Care. 2021;10(1):6-15.

119. **Wang Y**, Zheng Y, Tong Q, Wang L, Lv G, Xi Z, et al. Cardiac Injury and Clinical Course of Patients With Coronavirus Disease 2019. Front Cardiovasc Med. 2020;7:147.

120. **Wang Z**, Wang Z. Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak. BMC Infect Dis. 2021;21(1):113.

121. **Wu W**, Zhang X, Chen Y, Wang B, Wu J, Xiong Y, et al. Risk Factors of Fatal Outcome of Hospitalized Patients with COVID-19. Discov Med. 2021;31(164):121-7.

122. **Xu F**, Chen X, Yin X, Qiu Q, Xiao J, Qiao L, et al. Prediction of Disease Progression of COVID-19 Based upon Machine Learning. Int J Gen Med. 2021;14:1589-98.

123. **Xu JB**, Xu C, Zhang RB, Wu M, Pan CK, Li XJ, et al. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020;10(1):15058.

124. **Yang AP**, Li HM, Tao WQ, Yang XJ, Wang M, Yang WJ, et al. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients. Aging (Albany NY). 2020;12(11):10059-69.

125. **Yao Y**, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49.

126. **Ye W**, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res. 2020;21(1):169.

127. **Ye Y**, Wu X, Li X, Xu C, Wang Q, Yuan W, et al. Prediction and follow-up of risk factors for severe SARS-CoV-2 pneumonia and application of CT visual scoring. Technol Health Care. 2021;29(S1):153-64.

128. **Yu J**, Nie L, Wu D, Chen J, Yang Z, Zhang L, et al. Prognostic Value of a Clinical Biochemistry-Based Nomogram for Coronavirus Disease 2019. Front Med (Lausanne). 2020;7:597791.

129. **Yue T**, Zhou W, He J, Wang H, Liu Y, Wang B, et al. Combined clinical and imaging features better predict the critical outcomes of patients with SARS-COV-2. Medicine (Baltimore). 2021;100(12):e25083.

130. **Zeng HL**, Lu QB, Yang Q, Wang X, Yue DY, Zhang LK, et al. Longitudinal Profile of Laboratory Parameters and Their Application in the Prediction for Fatal Outcome Among Patients Infected With SARS-CoV-2: A Retrospective Cohort Study. Clin Infect Dis. 2021;72(4):626-33.

131. **Zhang J**, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med. 2020;18(1):406.

132. **Zhang L**, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-9.

133. **Zhao Y**, Nie HX, Hu K, Wu XJ, Zhang YT, Wang MM, et al. Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty. 2020;9(1):108.

134. **Zhao Y**, Yu C, Ni W, Shen H, Qiu M, Zhao Y. Peripheral blood inflammatory markers in predicting prognosis in patients with COVID-19. Some differences with influenza A. J Clin Lab Anal. 2021;35(1):e23657.

135. **Zhu F**, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(4):164-71.

136. **Zhu Y**, Du Z, Zhu Y, Li W, Miao H, Li Z. Evaluation of organ function in patients with severe COVID-19 infections. Med Clin (Engl Ed). 2020;155(5):191-6.


Identification of studies via databases and registers
Identification
Records identified from PubMed:
(n = 1,930)
Records removed for lack of original data;
e.g. identified on PubMed as book chapter,
review or systematic review, meta-analyses
(n = 279)
Screening
Records screened
(n = 1,651)
Reports excluded (n = 1,130)
Specific patient groups e.g. ITU (n = 451)
Specific focus e.g. VTE (n = 238)
Different geographical locations (n = 107)
No patient data e.g. editorial (n = 107)
Other e.g. cell/animal model (n = 273)
Reports assessed for eligibility
(n = 521)
Reports excluded:
No AUC data regarding biomarkers of
interest (n = 395)
Included
Studies included in review
(n = 130)
Reports included:
Original data from Cambridge, UK (Soon)
and Spain (Soares)
Reports referred from authors contacted

Pooled AUCs for biomarkers in SARS-CoV-2




A
CRP
Aloisio (Milan, Italy)
Antunez Muinos (A Coruña, Spain)
Creel (Georgia, USA)
Dolci (Milan, Italy)
Donoso-Navarro (Madrid, Spain)
Gatti (Turin, Italy)
Gavin (Indiana, USA)
Infante (Rome, Italy)
Laguna-Goya (Madrid, Spain)
Macias-Munoz (Barcelona, Spain)
Manocha (New York, USA)
Mueller (Boston, USA)
Muhammad (Washington DC, USA)
Myhre (Lørenskog, Norway)
Oliva (Rome, Italy)
Omland (Tubingen, Norway)
Pieri (Rome, Italy)
Peiro (Tarragona, Spain)
Pouw (Nijmegen, Netherlands)
Rubio-Rivas (nationwide, Spain)
Salinas (Sant Joan d'Alacant, Spain)
Santa Cruz (Braga, Portugal)
Smilowitz (New York, USA)
Soares (nationwide, Spain)
Soon (Cambridge, UK)
Turrini (Lombardy, Italy)
van Dam (Maastricht, Netherlands)
Vultaggio (Florence, Italy)
Europe/N. America
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AUC
Asia
Aksel (Istanbul, Turkey)
Asghar (Karachi, Pakistan)
Bastug (Ankara, Turkey)
Bilgir (Bozyaka/Izmir, Turkey)
Bintoro (Surabaya, Indonesia)
Chen FF (Wuhan, China)
Chen L (Beijing, China)
Cheng A (Wuhan, China)
Cheng B (Wuhan, China)
Duan J (Chongqing, China)
Fu J (Suzhou, China)
Gao Y (Anhui, China)
Genc (Sakarya, Turkey)
Guneysu (Sakarya, Turkey)
Han H (Wuhan, China)
Huang Y (Beijing, China)
Huang Y (Wuhan, China)
Keski (Istanbul, Turkey)
Li (Ningbo, China)
Li Y (Changsha, China)
Liang M (Wuhan, China)
Liu F (Wuhan, China)
Liu S (Hunan, China)
Luo X (Wuhan, China)
Luo Y (Wuhan, China)
Okuyan (Hatay, Turkey)
Otoshi (Yokohama, Japan)
Pan M (Hefei, China)
Qin JJ (Wuhan, China)
Ramesh (Wisakhapatnam, India)
Saji (Kanagawa, Japan)
Shang W (Wuhan, China)
Shi S (Yibin, China)
Tahtasakal (Istanbul, Turkey)
Wang D (Wuhan, China)
Wang F (Wuhan, China)
Wang M (Xiamen, China)
Wu W (Nanjing, China)
Xu (Suihua, China)
Ye Y (Hubei, China)
Yu J (Wuhan, China)
Yue T (Hubei, China)
Zeng HL (Wuhan, China)
Zhang J (Wuhan, China)
Zhang L (Wuhan, China)
Zhao (Wuhan, China)
Zhao Y (Wuhan, China)
B
D-dimer
Aloisio (Milan, Italy)
Antunez Muinos (A Coruña, Spain)
Chocron (Paris, France)
Creel (Atlanta, Georgia, USA)
Donoso-Navarro (Madrid, Spain)
Gavin (Indiana, USA)
Goudot (Paris, France)
Infante (Rome, Italy)
Laguna-Goya (Madrid, Spain)
Macias-Munoz (Barcelona, Spain)
Maeda (New York, USA)
Manocha (New York, USA)
Mueller (Boston, USA)
Myhre (Lørenskog, Norway)
Naymagon (New York, USA)
Omland (Lørenskog, Norway)
Pascual Gomez (Madrid, Spain)
Pieri (Rome, Italy)
Peiro (Tarragona, Spain)
Petersen-Uribe (Tübingen, Germany)
Pouw (Nijmegen,theNetherlands)
Rubio-Rivas (nationwide, Spain)
Salinas (Sant Joan d'Alacant, Spain)
Smilowitz (New York, USA)
Soares (nationwide, Spain)
Soon (Cambridge,UK)
Europe/N. America
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AUC
Asia
Asghar (Karachi, Pakistan)
Bastug (Ankara, Turkey)
Bilgir (Bozyaka/Izmir, Turkey)
Bintoro (Surabaya, Indonesia)
Chen H (Wuhan, China)
Chen L (Wuhan, China)
Chen X (Jingzhou, China)
Cheng A (Wuhan, China)
Cheng S (Jiangxi, China)
Duan J (Chongqing, China)
Fu J (Suzhou, China)
Genc (Sakarya,Turkey)
Gao Y (Anhui, China)
He X (Wuhan, China)
Huang Y (Wuhan, China)
Jin X (Wuhan, China)
Ke C (Wuhan, China)
Keski (Istanbul, Turkey)
Korkusuz (Istanbul, Turkey)
Kucukceran (Konya, Turkey)
Liang M (Wuhan, China)
Liu Q (Wuhan, China)
Long H (Wuhan, China)
Luo HC (Chongqing, China)
Luo Y (Wuhan, China)
Miki (Yokohama, Japan)
Okuyan (Hatay, Turkey)
Pan (Hefei, China)
Poudel (Bhaktapur, Nepal)
Qin JJ (Wuhan, China)
Qin ZJ (Wuhan, China)
Saji (Kanagawa, Japan)
Selcuk (Istanbul, Turkey)
Sharif (Islamabad, Pakistan)
Soni (Chennai, India)
Tahtasakal (Istanbul, Turkey)
Wang D (Wuhan, China)
Wang F (Wuhan, China)
Wang M (Xiamen, China)
Wang P (Jinan, China)
Wang Z (Wuhan, China)
Yang A (Zhejiang, China)
Xu F (Wuhan, China)
Yao Y (Wuhan, China)
Ye W (Wuhan, China)
Yu J (Wuhan, China)
Yue T (Hubei, China)
Zhang L (Wuhan, China)
Zhang J (Wuhan, China)
Zhu Y (Nanjing, China)


A
IL-6
Antunez Muinos (A Coruña, Spain)
Carlino (Naples, Italy)
Donoso-Navarro (Madrid, Spain)
Gavin (Indiana, USA)
Guirao (Ciudad Real, Spain)
Herold (Munich, Germany)
Infante (Rome, Italy)
Jontvedt (Oslo, Norway)
Laguna-Goya (Madrid, Spain)
Maeda (New York, USA)
Myhre (Lørenskog, Norway)
Nagant (Brussels, Belgium)
Pieri (Rome, Italy)
Quartuccio (Udine,Italy)
Ruscica (Milan, Italy)
Santa Cruz (Braga, Portugal)
Soares (nationwide, Spain)
Soon (Cambridge, UK)
Villa (Modena, Italy)
Europe/N. America
0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
AUC
Asia
Gao Y (Anhui, China)
Gu Y (Nanjing, China)
Ke C (Wuhan, China)
Han H (Wuhan, China)
Liu F (Wuhan, China)
Pan M (Hefei, China)
Satis (Ankara, Turkey)
Shang M (Wuhan, China)
Saji (Kanagawa, Japan)
Shi X (Henan, China)
Shi X (Henan, China)
Tang G (Wuhan, China)
Wang F (Wuhan, China)
Wang M (Xiamen, China)
Yang A (Zhejiang, China)
Yu J (Wuhan, China)
Zhang J (Wuhan, China)
Zhang J (Wuhan, China)
Zhao Y (Wuhan, China)
C
Troponin
Aloisio (Milan, Italy)
Cipriani (Padua, Italy)
de Michieli (Padova, Italy)
Goudot (Paris, France)
Harmouch (Pennsylvania, USA)
Herold (Munich, Germany)
Kaufmann (Vienna, Austria)
Macias-Munoz (Barcelona, Spain)
Manocha (New York, USA)
Myhre (Lørenskog, Norway)
Peiro (Tarragona, Spain)
Petersen-Uribe (Tübingen, Germany)
Salvatici (Rozzano, Italy)
Smilowitz (New York, USA)
Soares (Spain)
Soon (Cambridge, UK)
Europe/N. America
0.4 0.5 0.6 0.7 0.8 0.9 1.0
AUC
Asia
Asghar (Karachi, Pakistan)
Cao J (Wuhan, China)
Chen FF (Wuhan, China)
Chen L (Beijing, China)
Chen H (Wuhan, China)
Deng P (Wuhan, China)
Liang M (Wuhan, China)
Luo Y (Wuhan, China)
Ozdin (Sakarya, Turkey)
Ozyilmaz (Istanbul, Turkey)
Qin JJ (Wuhan, China)
Shi S (Wuhan, China)
Sun W (Wuhan, China)
Tahtasakal (Istanbul, Turkey)
Wang M (Xiamen, China)
Wang Y (Changchun, China)
Wang Y (Wuhan, China)
Zhang J (Wuhan, China)
Zhu F (Shanghai, China)
B
Urea
Carlino (Naples, Italy)
Kaufmann (Vienna, Austria)
Pascual-Gomez (Madrid, Spain)
Soon (Cambridge, UK)
Soares (nationwide, Spain)
van Dam (Maastricht, The Netherlands)
Europe/N. America
0.4 0.5 0.6 0.7 0.8 0.9 1.0
AUC
Asia
Asghar (Karachi, Pakistan)
Bilgir (Bozyaka/Izmir, Turkey)
Cheng A (Wuhan, China)
Cheng S (Guangzhou, China)
Ke C (Wuhan, China)
Liu Q (Wuhan, China)
Tahtasakal (Istanbul, Turkey)
Zhang J (Wuhan, China)
Zeng HL (Wuhan, China)
Zhu Y (Nanjing, China)
D
Age
Creel (Atlanta, Georgia, USA)
Macias-Munoz (Barcelona, Spain)
Mueller (Boston, USA)
Rubio-Rivas (nationwide, Spain)
Soon (Cambridge,UK)
Europe/N. America
0.4 0.5 0.6 0.7 0.8 0.9 1.0
AUC
Asia
Chen H (Wuhan, China)
Chen L (Wuhan, China)
Cheng S (Jiangxi, China)
Duan J (Chongqing, China)
Ke C (Wuhan, China)
Liang M (Wuhan, China)
Miki (Yokohama, Japan)
Qin ZJ (Wuhan, China)
Tahtasakal (Istanbul, Turkey)
Wang D (Wuhan, China)
Yang A (Zhejiang, China)


(A)
D-dimer
Wang (vaccinated, Omicron, Australia)
Rzymski (vaccinated, Delta, Poland)
Europe/N. America
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AUC
Asia
Patel (vaccinated, Omicron, India)
Altintop (vaccinated, Delta, Turkey)
(B)
CRP
Rzymski (vaccinated, Delta, Poland)
Wang (vaccinated, Omicron, Australia)
Europe/N. America
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AUC
Asia
Patel (vaccinated, Omicron, India)
Altintop (vaccinated, Delta, Turkey)